Member Info for undervaluedtoday

CelLBxHealth (formerly ANGLE plc) has successfully completed two development and validation contracts with AstraZeneca for circulating tumor cell (CTC) assays. The partnership focuses on utilizing CelLBxHealth’s Parsortix liquid biopsy platform to monitor drug efficacy and analyze tumor responses without invasive tissue biopsies.

Key Details of the PartnershipDNA Damage Assay: Under the initial contracts (totaling £820,000), CelLBxHealth developed and validated a DNA Damage assay and another unnamed assay for AstraZeneca’s clinical trials.Prostate Cancer (AR Assay): An extension agreement worth £550,000 was initiated to develop an Androgen Receptor (AR) assay. This enables the tracking of treatment responses and resistance mechanisms in patients with advanced prostate cancer.Contract Status: Both large pharma contracts were officially concluded in the first half of the company's fiscal year. The successful assay development is being leveraged to secure additional, larger-scale clinical trial contracts with other major pharmaceutical companies globally.

Technological IntegrationThe Parsortix system harvests intact, living cancer cells from routine blood draws. For AstraZeneca’s oncology pipeline, these isolated CTCs allow researchers to conduct:

3rd Resistance Point 4.675

2nd Resistance Point 4.525

1st Resistance Point 4.450

Last Price 4.488

☝️

💯

More like 50p+

And in the open market

Waky wakey

FARN De-Risked Development Path and Strong #BEXMAB Efficacy Drive Reiterated Buy on Faron and £10 Target

Faron Pharmaceuticals Oy, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a £10.00 price target.

The 5 analysts offering 12 month price targets for Faron Pharmaceuticals Oy have a median target of 77.82, with a high estimate of 328.58 and a low estimate of 51.88. The median estimate represents a 78.90% increase from the last price of 43.50.

https://markets.investorschronicle.co.uk/data/equities/tearsheet/forecasts?s=FARN:LSE

THIS IS significant news today

Https://www.proactiveinvestors.co.uk/companies/news/1092390/cellbxhealth-ceo-on-liquid-biopsy-opportunity-icymi-1092390.html

cellbxhealth ceo on liquid biopsy opportunity - icymi ********************26o83rxf @parsortix

Https://www.proactiveinvestors.co.uk/companies/news/211923/cellbxhealth-looks-to-change-the-game-for-cancer-detection-after-fda-approval-for-parsortix-211923.html

Https://www.proactiveinvestors.co.uk/companies/news/1092441/cellbxhealth-strikes-us-clinical-collaboration-with-adventhealth-cancer-studies-1092441.html

Https://pharmatimes.com/news/cellbxhealth-partners-with-adventhealth-on-ctc-based-monitoring-in-two-major-cancer-studies/

Year High 265.00

Year High Date 02-Jun-2025

Just the start of huge players taking a % of total supply ££££££££££

AdventHealth Palm Coast Highlights Growth, Innovation, and Community Commitment at State of the Hospital Event

By Danielle Anderson -May 17, 2026

https://www.flaglernewsweekly.com/adventhealth-palm-coast-highlights-growth-innovation-and-community-commitment-at-state-of-the-hospital-event/

Collaboration with AdventHealth for two studies monitoring CTCs to improve cancer care

· AdventHealth, one of the largest faith-based health systems in the United States

· CTC analysis will be an endpoint in two multi-centre studies in colon, gastrointestinal and lung cancer

Guildford, UK and Plymouth Meeting, U.S. - 18 May 2026 - CelLBxHealth plc (AIM:CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces a collaboration with AdventHealth, one of the largest faith-based health systems in the United States, for the use of CelLBxHealth's Parsortix® platform in two clinical studies. The studies, titled ACTION and SUNRISE, will employ minimally invasive cancer monitoring by isolating and analysing circulating tumour cells (CTCs) from patients undergoing treatment.

These studies mark an important advance in the use of minimally invasive diagnostics to better understand treatment response, improve outcomes, and expand access to precision oncology in community settings. Using the Parsortix platform, researchers will isolate and analyse CTCs from blood samples, enabling both enumeration and PD-L1 characterisation to provide real-time insight into tumour biology without the need for invasive biopsies.

The ACTION study (Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer) is a multi-site, NIH-funded trial currently enrolling 219 patients to evaluate how different doses of aerobic exercise influence chemotherapy tolerability in colon cancer patients (NCT05773144). The SUNRISE study (Statewide Unified Network for Remote Intervention of Strength and Exercise) is a digitally enabled trial in 120 patients with gastrointestinal and lung cancers, assessing whether remotely delivered exercise interventions can improve chemotherapy tolerance and quality of life expected to commence in July 2026. Across both studies, CTC analysis will serve as a novel correlative endpoint, helping researchers understand how the tumour evolves in response to treatment and behavioural interventions.

A central aim of both studies is to enable more patient-centric care by bringing advanced cancer monitoring closer to patients' homes. With most cancer patients in the United States treated in the community, the combination of remote interventions and simple blood-based diagnostics has the potential to reduce patient burden, minimise travel, and support continuous monitoring regardless of location. This approach also addresses persistent health inequalities that limit access to specialised cancer care, particu

Blood Cancer United, Inc.

City and country of registered office (if applicable) Washington, D.C., United States of America

Blood Cancer United, Inc. is the official new name of the Leukemia & Lymphoma Society (LLS). Rebranded in late 2025 to create a more inclusive, easily understood identity, it stands as the world's leading 501(c)(3) voluntary health organization entirely dedicated to funding blood cancer research, patient support, and healthcare advocacy.

Mission: Cure leukemia, lymphoma, Hodgkin's disease, myeloma, and other blood cancers while improving the quality of life for patients and their families.Bold Goal: To collectively help blood cancer patients gain over 1 million years of life by 2040.History: Founded in 1949 by Rudolph and Antoinette Roesler de Villiers. It operated under names like the Leukemia Society of America before becoming LLS, and ultimately transitioning to Blood Cancer United.Leadership: Led by President and CEO E. Anders Kolb, MD.Headquarters: 1201 15th Street N.W., Suite 410, Washington, D.C. 20005.

Core Mission AreasResearch Funding: As the single largest non-profit funder of blood cancer research, they have invested over $1.8 billion globally. The organization has helped advance more than 70% of blood cancer treatments approved by the FDA over the last two decades.Therapy Acceleration Program® (TAP): A specialized strategic initiative that invests directly in biotech companies to fast-track innovative drugs from academic labs into clinical trials.Patient Support Services: The charity provides extensive free resources, including access to specialized oncology social workers, clinical trial nurse navigators, and registered dietitians. They also run financial assistance initiatives like the Urgent Need Program.Advocacy: Mobilises a network of volunteers to influence public policy, ensuring patients secure access to quality, coordinated, and affordable cancer therapies.

Signature Events & EngagementLight The Night: Their flagship national evening walk event where communities carry illuminated lanterns—white for survivors, gold to remember lost loved ones, and red for supporters—to raise critical treatment funds.Community Campaigns: Features alternative fundraising tracks such as Visionaries of the Year and Team In Training.

⚡